Yahoo
NasdaqGS - Delayed Quote USD

PMV Pharmaceuticals, Inc. (PMVP)

1.7900 +0.0400 (+2.29%)
At close: October 2 at 4:00:00 PM EDT
1.7900 0.0000 (0.00%)
After hours: October 2 at 7:30:04 PM EDT
Chart Range Bar
Loading chart for PMVP
  • Previous Close 1.7500
  • Open 1.7500
  • Bid 1.3400 x 200
  • Ask 1.8000 x 900
  • Day's Range 1.6800 - 1.8700
  • 52 Week Range 1.0200 - 1.9100
  • Volume 3,735,753
  • Avg. Volume 629,501
  • Market Cap (intraday) 95.69M
  • Beta (5Y Monthly) 1.37
  • PE Ratio (TTM) --
  • EPS (TTM) -1.4500
  • Earnings Date (est.) Nov 16, 2026
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 4.20

PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule therapies targeting p53 mutations and other p53-related cancers in the United States. It develops rezatapopt, a selective structural corrector of p53 Y220C mutations in Phase 2 clinical trials for tumor agnostic diseases. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Princeton, New Jersey.

www.pmvpharma.com

54

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Performance Overview

Trailing total returns as of 10/2/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

PMVP
43.20%
S&P 500 (^GSPC)
12.81%

1-Year Return

PMVP
29.71%
S&P 500 (^GSPC)
15.00%

3-Year Return

PMVP
69.87%
S&P 500 (^GSPC)
80.08%

5-Year Return

PMVP
94.08%
S&P 500 (^GSPC)
77.25%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY26
Revenue --
Earnings -18.09M
Profit Margin 0.00%

Q3

FY25

Q4

FY25

Q1

FY26

Q2

FY26

-20M
-15M
-10M
-5M
0
0.0%

Analyst Insights

View More

Analyst Price Targets

3.00
4.20 Average
1.7900 Current
5.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 9/4/2026
Analyst HC Wainwright & Co.
Rating Action Reiterates
Rating Buy
Price Action Maintains
Price Target 5 -> 5

Statistics

View More

Valuation Measures

Annual
As of 9/23/2026
  • Market Cap

    73.77M

  • Enterprise Value

    -5.44M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    1.03

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -42.39%

  • Return on Equity (ttm)

    -70.93%

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -75.22M

  • Diluted EPS (ttm)

    -1.4500

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    79.43M

  • Total Debt/Equity (mrq)

    0.30%

  • Levered Free Cash Flow (ttm)

    -43.82M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Fair Value

1.7900 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: